Andreas Grassauer

ORCID: 0000-0003-3715-2545
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Echinoderm biology and ecology
  • Pediatric health and respiratory diseases
  • Influenza Virus Research Studies
  • Respiratory viral infections research
  • Monoclonal and Polyclonal Antibodies Research
  • Immunotherapy and Immune Responses
  • Virus-based gene therapy research
  • Immune Response and Inflammation
  • Viral Infections and Immunology Research
  • Viral gastroenteritis research and epidemiology
  • Immune Cell Function and Interaction
  • Allergic Rhinitis and Sensitization
  • Seaweed-derived Bioactive Compounds
  • HIV Research and Treatment
  • Mast cells and histamine
  • T-cell and B-cell Immunology
  • CAR-T cell therapy research
  • Antimicrobial Peptides and Activities
  • Viral-associated cancers and disorders
  • Phytochemical Studies and Bioactivities
  • Cervical Cancer and HPV Research
  • Neuropeptides and Animal Physiology
  • Wireless Body Area Networks
  • Advanced Chemical Sensor Technologies
  • Diverse Scientific Research Studies

Marinomed Biotech (Austria)
2008-2023

University of Vienna
2002-2004

Austrian Society of Dermatology and Venereology
2002

Medical University of Vienna
2001

BOKU University
1998

ABSTRACT We established a reverse genetics system for the nonstructural (NS) gene segment of influenza A virus. This is based on use temperature-sensitive ( ts ) reassortant virus 25A-1. The 25A-1 contains NS from A/Leningrad/134/57 and remaining segments A/Puerto Rico (PR)/8/34 particular constellation was found to be responsible phenotype. For gene, plasmid-derived A/PR/8/34 ribonucleoprotein transfected into cells that were previously infected with Two subsequent passages transfection...

10.1128/jvi.72.8.6437-6441.1998 article EN Journal of Virology 1998-08-01

Human rhinoviruses (HRVs) are the predominant cause of common cold. In addition, HRVs implicated in worsening COPD and asthma, as well loss lung transplants. Despite significant efforts, no anti-viral agent is approved for prevention or treatment HRV-infection. this study we demonstrate that Iota-Carrageenan, a sulphated polysaccharide derived from red seaweed, potent anti-rhinoviral substance in-vitro. Iota-Carrageenan reduces HRV growth inhibits virus induced cythopathic effect infected...

10.1186/1743-422x-5-107 article EN cc-by Virology Journal 2008-01-01

The 2009 flu pandemic and the appearance of oseltamivir-resistant H1N1 influenza strains highlight need for treatment alternatives. One such option is creation a protective physical barrier in nasal cavity. In vitro tests demonstrated that iota-carrageenan potent inhibitor A virus infection, most importantly also H1N1/2009 vitro. Consequently, we tested commercially available spray containing an mouse infection model. Treatment mice infected with lethal dose PR8/34 starting up to 48 hours...

10.1371/journal.pone.0014320 article EN cc-by PLoS ONE 2010-12-14

Clinical trials applying iota-carrageenan nasal spray have previously shown to reduce duration of virus-confirmed common cold. The present study pooled data two similar clinical provide further evidence for the antiviral effectiveness carrageenan. Individual patient were analyzed from randomized double blind placebo controlled assessing therapeutic carrageenan in acute Patients with cold (n = 254, verum 126, 128) included and following parameters appraised: disease, number patients relapses,...

10.1186/2049-6958-9-57 article EN cc-by-nc Multidisciplinary Respiratory Medicine 2014-01-01

In the absence of a vaccine and other effective prophylactic or therapeutic countermeasures severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) remains significant public health threat. Attachment entry coronaviruses including SARS-CoV-2 is mainly mediated by spike glycoprotein. Here, we show that iota-carrageenan can inhibit cell pseudotyped lentivirus in dose dependent manner. particles were efficiently neutralized with an IC50 value 2.6 μg/ml iota-carrageenan. Experiments...

10.1371/journal.pone.0237480 article EN cc-by PLoS ONE 2021-02-17

Objective To investigate whether variations of the conserved gp41 amino-acid sequence ELDKWA affect its binding or neutralization by monoclonal antibody (MAb) 2F5. Design and methods Neutralization assays were performed with primary isolates from different HIV-1 subtypes sequences corresponding to 2F5 epitope region analysed. Studies MAb peptide reactivity spot analysis, using peptides immobilized on cellulose. The frequency emergence neutralization-resistant virus variants was determined...

10.1097/00002030-199606000-00003 article EN AIDS 1996-06-01

The common cold, the most prevalent contagious viral disease in humans still lacks a safe and effective antiviral treatment. Iota-Carrageenan is broadly active against respiratory viruses in-vitro has an excellent safety profile. This study investigated efficacy of nasal spray patients with cold symptoms. In randomized, double-blind, placebo-controlled exploratory trial, 35 human subjects suffering from early symptoms received (0.12%) saline solution three times daily for 4 days, compared to...

10.1186/1465-9921-11-108 article EN cc-by Respiratory Research 2010-08-10

Abstract Background The common cold is the most widespread viral infection in humans. Iota-carrageenan has previously shown antiviral effectiveness against viruses clinical trials. This study investigated efficacy of a carrageenan-containing nasal spray on duration and fluid load adult patients. Methods In randomized, double-blind, placebo-controlled trial, 211 patients suffering from early symptoms were treated for seven days. Application was performed three times daily with either...

10.1186/1465-9921-14-124 article EN cc-by Respiratory Research 2013-11-13

Previously, we constructed a chimeric influenza virus that expresses the highly conserved amino acid sequence ELDKWA of gp41 human immunodeficiency type 1 (HIV-1). Antisera elicited in mice by infection with this showed neutralizing activity against distantly related HIV-1 isolates (T. Muster, R. Guinea, A. Trkola, M. Purtscher, Klima, F. Steindl, P. Palese, and H. Katinger, J. Virol. 68:4031-4034, 1994). In present study, demonstrated intranasal immunizations are also able to induce humoral...

10.1128/jvi.69.11.6678-6686.1995 article EN Journal of Virology 1995-11-01

The baculovirus expression system was utilized to serve as a tool for ligand selection, demonstrating the applicability of generation and screening eukaryotic libraries. HIV-1-gp41 epitope 'ELDKWA', specific neutralizing human mAb 2F5, inserted into antigenic site B influenza virus hemagglutinin expressed on surface infected insect cells. In order improve antigenicity within hemagglutinin, therefore enhance binding we three additional, random amino acids adjacent epitope. This pool genes...

10.1093/nar/26.7.1718 article EN Nucleic Acids Research 1998-04-01

ABSTRACT Human rhinoviruses (HRVs) are the predominant cause of common cold. The frequency HRV infections in industrial countries and lack effective therapeutical treatment underline importance research for new antiviral substances. As viral often accompanied by generation oxidative stress inside infected cells, several redox-active substances were tested as potential antivirals. In course these studies it was discovered that pyrrolidine dithiocarbamate (PDTC) is an extremely potent compound...

10.1128/jvi.76.12.6004-6015.2002 article EN Journal of Virology 2002-06-15

Background Carrageenan is a clinically proven and marketed compound for the treatment of viral upper respiratory tract infections. As infections caused by influenza virus are often accompanied with other viruses combination specific anti-influenza broadly active antiviral polymer has huge potential Thus, drug Zanamivir together carrageenan in formulation suitable intranasal application was evaluated in-vitro in-vivo. Principal Findings We show that act synergistically against several A...

10.1371/journal.pone.0128794 article EN cc-by PLoS ONE 2015-06-08

Carrageenan has been widely used as food additive for decades and therefore, an extended oral data set is available in the public domain. Less are other routes of administration, especially intranasal administration. The current publication describes non-clinical safety toxicity native (non-degraded) iota-carrageenan when applied intranasally or via inhalation. Intranasally a topically applied, locally acting compound with no need systemic bioavailability drug's action. Animal experiments...

10.1371/journal.pone.0122911 article EN cc-by PLoS ONE 2015-04-13

The COVID-19 pandemic continues to spread around the world and remains a major public health threat. Vaccine inefficiency, vaccination breakthroughs lack of supply, especially in developing countries, as well fact that non-negligible part population either refuse or cannot be vaccinated due age, pre-existing illness non-response existing vaccines intensify this issue. This might also contribute emergence new variants, being more efficiently transmitted, virulent capable escaping naturally...

10.3390/ijms222413202 article EN International Journal of Molecular Sciences 2021-12-08

Abstract NS1 protein of influenza virus is a virulence factor that counteracts Type I interferon (IFN)‐mediated antiviral response by the host. A recombinant lacks only replicates efficiently in systems contain defective IFN pathways. We demonstrate conditional replication properties NS1‐modified mutants can be exploited for virus‐mediated oncolysis IFN‐resistant tumor cells. resistance analyzed cell lines correlated with reduced expression STAT1. Addition exogenous IFNα or supernatant...

10.1002/ijc.20078 article EN International Journal of Cancer 2004-02-09

Neutralization capsid epitopes are important determinants for antibody-mediated immune protection against papillomavirus (PV) infection and induced disease. Chimeric L1 major proteins of the human PV type 16 (HPV-16) bovine 1 (BPV-1) with a foreign peptide incorporated into several surface loops self-assembled pentamers or virus-like particles (VLP). Binding patterns neutralizing monoclonal antibodies (MAb) immunization mice confirmed (i) that regions around aa 282–286 351–355 contribute to...

10.1099/0022-1317-82-11-2799 article EN Journal of General Virology 2001-11-01

Abstract We previously described the expression of melanoma-associated endogenous retrovirus (MERV) proteins and viral particles in human melanomas metastases. The objective present study was to determine whether a humoral immune response MERV occurs melanoma. Candidate B-cell epitopes on were predicted using bioinformatic screening. reactivity peptides corresponding with antibodies prevalent sera melanoma patients analyzed. An immunodominant peptide located env protein identified....

10.1158/0008-5472.can-05-2452 article EN Cancer Research 2006-02-01

Previously, a mucosal model of immunization against human immunodeficiency virus type 1 (HIV-1) was established by using influenza as vector for the neutralizing gp41 epitope ELDKWA. Whether replication this chimeric in upper respiratory tract mice is sufficient inducing immune responses genital investigated. An strategy that permits to replicate murine tracts but not lungs. Intranasal application induced HIV-1-specific antibodies sera and tract. In addition, virus-specific...

10.1086/314445 article EN The Journal of Infectious Diseases 1998-11-01

Abstract Background Type I hypersensitivity is characterized by the overreaction of immune system against otherwise innocuous substances. It manifests as allergic rhinitis, conjunctivitis, asthma or atopic dermatitis if mast cells are activated in respective organs. In case systemic cell activation, life-threatening anaphylaxis may occur. Currently, type hypersensitivities treated either with glucocorticoids, anti-histamines, stabilizers. Although these drugs exert a strong anti-allergic...

10.1186/1471-2172-11-24 article EN cc-by BMC Immunology 2010-05-21


 Background: Clinical trials applying iota-carrageenan nasal spray have previously shown to reduce duration of virus-confirmed common cold. The present study pooled data two similar clinical provide further evidence for the antiviral effectiveness carrageenan.
 Methods: Individual patient were analyzed from randomized double blind placebo controlled assessing therapeutic carrageenan in acute Patients with cold (n = 254, verum 126, 128) included and following parameters appraised:...

10.4081/mrm.2014.392 article EN cc-by-nc Multidisciplinary Respiratory Medicine 2014-11-14

<b><i>Background:</i></b> Current standard medications for the treatment of allergic inflammation consist primarily glucocorticoids and anti-histamines, but adverse side effects or insufficient responsiveness by patient subpopulations illustrate need safe novel alternatives. Thus, there is a demand to develop porcine model that able mimic mast cell-mediated type I hypersensitivity. Previously, we found escin, pharmacologically active mix triterpene saponins from horse...

10.1159/000343289 article EN International Archives of Allergy and Immunology 2012-12-14

Abstract In the absence of a vaccine and other effective prophylactic or therapeutic countermeasures severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) remains significant public health threat. Attachment entry coronaviruses including SARS-CoV-2 is mediated by spike glycoprotein (SGP). Recently, Spike Pseudotyped Lentivirus (SSPL) was developed that allows studying spike-mediated cell via luciferase reporter activity in BSL2 environment. Here, we show iota-carrageenan can...

10.1101/2020.07.28.224733 preprint EN cc-by-nd bioRxiv (Cold Spring Harbor Laboratory) 2020-07-28

Even with its endemic transition, the COVID-19 pandemic remains a public health threat, particularly in light of emerging variants concern (VoCs) and need for preparedness future. In November 2021, SARS-CoV-2 VoC Omicron emerged subvariants BA.1, BA.2 BA.5 became predominant. Although protease inhibitor Paxlovid® polymerase inhibitors Molnupiravir Remdesivir were approved as specific antiviral treatment options patients early stages after infection, effective prophylactically acting...

10.3390/nutraceuticals3030025 article EN cc-by Nutraceuticals 2023-07-05
Coming Soon ...